Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Solomon Nuhoho, Jeffrey Vietri & Melany Worbes-Cerezo. (2017) Increased cost of illness among European patients with type 2 diabetes treated with insulin. Current Medical Research and Opinion 33:1, pages 47-54.
Read now
Read now
Marc Evans, Henrik Holm Jensen, Mette Bøgelund, Jens Gundgaard, Barrie Chubb & Kamlesh Khunti. (2013) Flexible insulin dosing improves health-related quality-of-life (HRQoL): a time trade-off survey. Journal of Medical Economics 16:11, pages 1357-1365.
Read now
Read now
Kerstin Brismar, Marianna Benroubi, Claudia Nicolay, Henry Schmitt, Joseph Giaconia & Matthew Reaney. (2013) Evaluation of insulin initiation on resource utilization and direct costs of treatment over 12 months in patients with type 2 diabetes in Europe: results from INSTIGATE and TREAT observational studies. Journal of Medical Economics 16:8, pages 1022-1035.
Read now
Read now
Stephen Jones, Conxa Castell, Albert Goday, Helen T Smith, Claudia Nicolay, Alexander Simpson & Carole Salaun-Martin. (2012) Increase in direct diabetes-related costs and resource use in the 6 months following initiation of insulin in patients with type 2 diabetes in five European countries: data from the INSTIGATE study. ClinicoEconomics and Outcomes Research 4, pages 383-393.
Read now
Read now
Stephen Jones, Marian Benroubi, Conxa Castell, Albert Goday, Andreas Liebl, Louise Timlin, Claudia Nicolay, Alexander Simpson & Aodan Tynan. (2009) Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study*. Current Medical Research and Opinion 25:3, pages 691-700.
Read now
Read now
Oliver Schöffski, Lusine Breitscheidel, Ursula Benter, Franz-Werner Dippel, Markus Müller, Michael Volk & Martin Pfohl. (2008) Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study. Journal of Medical Economics 11:4, pages 695-712.
Read now
Read now
Articles from other publishers (16)
Anna Scherdjow, Sophie Kiefer, Jonas Lüske & Annina Eva Althaus. (2022) The Global Threat of Non-Communicable Diseases – Cost and
Drivers for Diabetes Type 2 in Germany. Gesundheitsökonomie & Qualitätsmanagement 28:01, pages 34-40.
Crossref
Crossref
Rena R. Wing. (2021) Does Lifestyle Intervention Improve Health of Adults with Overweight/Obesity and Type 2 Diabetes? Findings from the Look AHEAD Randomized Trial. Obesity 29:8, pages 1246-1258.
Crossref
Crossref
Tobias Effertz, Susanne Engel, Frank Verheyen & Roland Linder. (2015) The costs and consequences of obesity in Germany: a new approach from a prevalence and life-cycle perspective. The European Journal of Health Economics 17:9, pages 1141-1158.
Crossref
Crossref
Thomas Lehnert, Alexander Konnopka & Hans-Helmut König. (2016) Übergewicht und Adipositas als Public Health-Problem. Public Health Forum 24:2, pages 135-138.
Crossref
Crossref
Linong Ji, Shih-Tzer Tsai, Jay Lin & Sanjiv Bhambani. (2015) National Variations in Comorbidities, Glycosylated Hemoglobin Reduction, and Insulin Dosage in Asian Patients with Type 2 Diabetes: The FINE-Asia Registry. Diabetes Therapy 6:4, pages 519-530.
Crossref
Crossref
Andreas LieblKamlesh KhuntiDomingo Orozco-BeltranJean-Francois Yale. (2015) Health Economic Evaluation of Type 2 Diabetes Mellitus: A Clinical Practice Focused Review. Clinical Medicine Insights: Endocrinology and Diabetes 8, pages CMED.S20906.
Crossref
Crossref
Mark A. Espeland, Henry A. Glick, Alain Bertoni, Frederick L. Brancati, George A. Bray, Jeanne M. Clark, Jeffrey M. Curtis, Caitlin Egan, Mary Evans, John P. Foreyt, Siran Ghazarian, Edward W. Gregg, Helen P. Hazuda, James O. Hill, Don Hire, Edward S. Horton, Van S. Hubbard, John M. Jakicic, Robert W. Jeffery, Karen C. Johnson, Steven E. Kahn, Tina Killean, Abbas E. Kitabchi, William C. Knowler, Andrea Kriska, Cora E. Lewis, Marsha Miller, Maria G. Montez, Anne Murillo, David M. Nathan, Ebenezer Nyenwe, Jennifer Patricio, Anne L. Peters, Xavier Pi-Sunyer, Henry Pownall, J. Bruce Redmon, Julia Rushing, Donna H. Ryan, Monika Safford, Adam G. Tsai, Thomas A. Wadden, Rena R. Wing, Susan Z. Yanovski & Ping Zhang. (2014) Impact of an Intensive Lifestyle Intervention on Use and Cost of Medical Services Among Overweight and Obese Adults With Type 2 Diabetes: The Action for Health in Diabetes. Diabetes Care 37:9, pages 2548-2556.
Crossref
Crossref
Christin Bexelius, Johan Lundberg, Xuan Wang, Jenny Berg & Hans Hjelm. (2013) Annual Medical Costs of Swedish Patients with Type 2 Diabetes Before and After Insulin Initiation. Diabetes Therapy 4:2, pages 363-374.
Crossref
Crossref
Kyriakos Aloumanis, Marianna Benroubi, Sotiria Sourmeli & Vangelis Drossinos. (2013) Clinical outcomes and costs for patients with type 2 diabetes mellitus initiating insulin therapy in Greece: Two-year experience from the INSTIGATE study. Primary Care Diabetes 7:3, pages 235-242.
Crossref
Crossref
Athena Philis-Tsimikas, Meryl Brod, Marcus Niemeyer, Ann Marie Ocampo Francisco & Jeffrey Rothman. (2013) Insulin Degludec Once-Daily in Type 2 Diabetes: Simple or Step-Wise Titration (BEGIN: Once Simple Use). Advances in Therapy 30:6, pages 607-622.
Crossref
Crossref
Ana Vieta, Xavier Badia & José A. Sacristán. (2011) A Systematic Review of Patient-Reported and Economic Outcomes: Value to Stakeholders in the Decision-Making Process in Patients With Type 2 Diabetes Mellitus. Clinical Therapeutics 33:9, pages 1225-1245.
Crossref
Crossref
Thomas von Lengerke & Christian Krauth. (2011) Economic costs of adult obesity: A review of recent European studies with a focus on subgroup-specific costs. Maturitas 69:3, pages 220-229.
Crossref
Crossref
María Costi, Helen Smith, Jesús Reviriego, Conxa Castell, Alberto Goday & Tatiana Dilla. (2011) Costes directos sanitarios en pacientes con diabetes mellitus tipo 2 a los seis meses de inicio del tratamiento con insulina en España: estudio INSTIGATE. Endocrinología y Nutrición 58:6, pages 274-282.
Crossref
Crossref
Mar?a Costi, Helen Smith, Jes?s Reviriego, Conxa Castell, Alberto Goday & Tatiana Dilla. (2011) Direct health care costs in patients with type 2 diabetes mellitus six months after starting insulin treatment in Spain: The INSTIGATE Study. Endocrinolog?a y Nutrici?n (English Edition) 58:6, pages 274-282.
Crossref
Crossref
T. Mittendorf, J. Smith-Palmer, L. Timlin, M. Happich & G. Goodall. (2009) Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting. Diabetes, Obesity and Metabolism 11:11, pages 1068-1079.
Crossref
Crossref
M. Varroud-Vial. (2008) L’insulinothérapie du diabète de type 2 : quelle organisation des soins, quel rôle pour le médecin généraliste et les paramédicaux ? Pour quels coûts de santé ?. Médecine des Maladies Métaboliques 2, pages S183-S188.
Crossref
Crossref